3.10Open3.10Pre Close0 Volume2 Open Interest5.00Strike Price0.00Turnover0.00%IV-2.70%PremiumApr 17, 2025Expiry Date3.15Intrinsic Value100Multiplier0DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma0.58Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Stereotaxis Stock Discussion
2 MINUTES AGO, 7:31 AM EST
VIA GLOBENEWSWIRE
ST. LOUIS, March 03, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced FDA regulatory submission for the MAGiC Sweep™ catheter. MAGiC Sweep is the first high-density EP mapping catheter developed to b...
Game-Changing Medical Robot Fits Under OR Table: European Hospital First to Order Stereotaxis' Compact GenesisX
GlobeNewswire· 2 mins ago
ST. LOUIS, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it has received the first order for its latest generation robotic system, GenesisX.
"We are thrilled to announce the first firm order for GenesisX from a pioneering European hospital," said David Fischel...
Stereotaxis Announces First GenesisX Robotic System Order
Thursday, 30th January at 8:09 am
ST. LOUIS, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it has received the first order for its latest generation robotic system, GenesisX™.
"We are thrilled to announce the first firm order for GenesisX from a pioneering European hospital," said Da...
Stereotaxis Receives CE Mark Approval for the MAGiC Ablation Catheter
Monday, 27th January at 8:00 am
ST. LOUIS, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it received European CE Mark approval for the MAGiC™ ablation catheter. This approval is a significant milestone for Stereotaxis and for the community of physicians pioneering rob...
Oulu University Hospital Enhances Leadership in Arrhythmia Care with Advanced Genesis Robotic Technology
Tuesday, 14th January at 7:21 am
ST. LOUIS, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that physicians at Oulu University Hospital in Finland have successfully treated the first patients using the advanced Genesis Robotic Magnetic Navig...
Benzinga· 3 mins ago
Magbot Robotic Magnetic Navigation Ablation Catheter Approved by China's NMPA
20 seconds ago, 4:25 AM PST
Via GlobeNewswire
ST. LOUIS and SHANGHAI, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS) and Shanghai MicroPort EP Medtech Co., Ltd. (688351.SH, "MicroPort EP"), today announced that the Magbot™ Magnetic Navigation Ablation Catheter has received regulatory approval from China's National Medical Products Administration (NMPA).
The Magbot™ Catheter is ...
Stereotaxis’ GenesisX Robotic System to be Showcased for the First Time at RSNA 2024 by Neusoft Medical Systems
Stereotaxis (NYSE: STXS) announced that its latest GenesisX robotic system is being featured at Neusoft Medical Systems' booth during RSNA 2024, the world's premier radiology forum in Chicago. The system is being showcased alongside Neusoft's NeuAngio 30F fluoroscopy system, marking a growing collaboration between the companies to integrate and commercializ...
No comment yet